Quick Answer
Keros Therapeutics, Inc. reported R&D Expense of $129.64 million for fiscal year 2025.
Keros Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $129.64M | -25.3% |
| 2024 | $173.63M | +28.4% |
| 2023 | $135.26M | +55.0% |
| 2022 | $87.27M | +58.3% |
| 2021 | $55.14M | +62.9% |
| 2020 | $33.86M | +94.8% |
| 2019 | $17.38M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $19.52M | -60.3% | -55.1% |
| June 30, 2025 | $43.50M | +7.4% | -10.7% |
| March 31, 2025 | $48.71M | +27.3% | -1.0% |
| September 30, 2024 | $49.23M | +44.2% | +21.5% |
| June 30, 2024 | $40.52M | +24.5% | +5.9% |
| March 31, 2024 | $38.26M | +23.1% | +12.1% |
| September 30, 2023 | $34.14M | +62.3% | +4.9% |
| June 30, 2023 | $32.53M | +39.7% | +4.6% |
- Keros Therapeutics, Inc. showed a decrease of -25.3% in R&D Expense compared to the prior fiscal year.
- Over the 2019–2025 period, Keros Therapeutics, Inc.’s r&d expense has grown by 646.0% (from $17.38 million to $129.64 million).
- The most recent figure is from Keros Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 4, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: